A variety of receptors on pancreatic acinar and duct cells regulate both pancreatic exocrine secretion and intracellular processes. These receptors are potential sites of action for therapeutic agents in the treatment of pancreatitis.
Potent agonists and antagonists are becoming increasingly available for receptors involved in regulating the function of the gastrointestinal tract, including the exocrine pancreas. One of the first applications of such agents to clinical practice has been the use of secretin with or without cholecystokinin (CCK) or its analog caerulein in testing pancreatic exocrine secretory function [1] . More recently, the development of CCK and secretin receptor antagonists and of octreotide, a clinically useful analog of somatostatin, has raised the prospect that therapies directed at modulating hormonal regulation of the pancreas may prove useful in treating acute or chronic pancreatitis.
CCK RECEPTOR ANTAGONISTS Evidence that CCK may contribute to the severity of acute pancreatitis has come from a report in which caerulein, a CCK analog, was described as worsening the severity and mortality of acute pancreatitis produced in rats by intraductal injections of bile salts [2] and from numerous studies in the rat (e.g., [3] ) and the mouse (e.g., [4] ) in which supramaximal stimulation with caerulein produced acute pancreatitis. Such findings suggested that CCK receptor blockade might have a beneficial effect in mitigating the severity of acute pancreatitis.
At least in the rat, caerulein-induced acute pancreatitis appears to be due to the interaction of caerulein with a low-affinity CCK receptor which is involved in high-dose inhibition of enzyme secretion by the pancreas [5] . CCK receptor antagonists would thus be expected to reduce the severity of acute pancreatitis or, if given as a pre-treatment in sufficient amount, to prevent it. This result is indeed the case (Fig.  1 ) [4, 6] .
It is hardly surprising that a CCK receptor antagonist can prevent acute pancreatitis produced by excessive stimulation with a CCK analog. A more intriguing observation was the finding that proglumide (a glutaramic acid-derivative CCK receptor antagonist) reduced the severity of injury and significantly improved survival in a necrotizing, highly lethal form of pancreatitis produced in mice by feeding a choline-deficient, ethionine-supplemented (CDE) diet [7] . Proglumide was effective whether administered prior to or following initiation of acute pancreatitis ( Fig. 2) , under conditions in which plasma CCK levels were not elevated [7] . Similar effects in CDE diet-induced acute pancreatitis have been reported for the more potent glutaramic acid-derivative CCK receptor antagonist lorglumide (CR-1409) [8] .
Direct beneficial effects of CCK receptor antagonists have also been reported in other models of acute pancreatitis which do not involve supramaximal stimulation of the pancreas by CCK, caerulein, or other ligands which bind to the CCK receptor. Glutaramic acid-derived antagonists mitigated the severity of acute pancreatitis produced in rats by supramaximal stimulation with a cholinergic agonist [9] or by direct injection of taurocholate into the pancreatic parenchyma [10] . Members of a different structural class of CCK receptor antagonist (asperlicin and its derivatives, related structurally to the benzodiazepines) improved survival and reduced the biochemical and morphological severity in experimental acute pancreatitis produced by perfusion of the pancreatic duct by sodium taurocholate in the rat [11, 12] or by mechanical trauma in the guinea pig [12] .
Other important factor in the pathophysiology of acute pancreatitis. Fasted rats had a reduction in plasma CCK concentration and less severe caerulein-induced pancreatitis than did fed rats [13] . A similar degree of improvement was observed when the fed rats were treated with the CCK receptor antagonist loxiglumide (a glutaramic acid derivative). In another report [14] , the severity of CDE diet-induced pancreatitis in mice was markedly reduced by feeding animals taurocholate, a bile salt which reduces plasma CCK levels by inhibiting CCK release from the small intestine (Fig.  3) . Conversely, bile salt depletion by feeding cholestyramine led to an increase in plasma CCK concentration and worsened pancreatitis. This deleterious effect of cholestyramine could be blocked by administration of loxiglumide, just as the beneficial effects of taurocholate feeding could be blocked by giving animals CCK.
Not all studies, however, have observed beneficial effects of CCK receptor antagonists in experimental models of acute pancreatitis. Administration of the asperlicin derivative devazepide (formally designated as MK-329 or L-364,718), one of the most potent inhibitors of CCK-stimulated enzyme secretion by the pancreas, failed to show a beneficial effect in CDE diet-induced pancreatitis even at doses which markedly reduced the severity of caerulein-induced pancreatitis [15, 16] . Other investigators did not observe a beneficial effect of loxiglumide when given to rats with acute pancreatitis induced by taurocholate infusion into the pancreatic duct [17] .
Thus far the conflicting data resulting from the use of different CCK receptor antagonists in different models of acute pancreatitis have defied explanation. Positive results have, however, now been reported by at least five different groups of investigators, using four different models (caerulein stimulation, CDE diet, taurocholate perfusion of the pancreatic duct, and trauma) in three different species (rat, mouse, and guinea pig). This In CDE diet-induced acute pancreatitis in mice, taurocholate feeding decreased plasma CCK levels and improved survival compared to the control. Conversely, cholestyramine feeding increased plasma CCK levels and decreased survival.
b. The protective effect of taurocholate feeding was reduced when CCK was administered (taurocholate + CCK-8), whereas administration of the glutaramic acid-derived CCK receptor antagonist lorglumide (cholestyramine + CR-1409) improved survival in cholestyramine-fed animals. These findings suggest that CCK is contributing to the severity of the acute pancreatitis produced in this model (from [14] , reprinted with permission).
asperlicin derivative devazepide suggest that the beneficial effects of the former may be regulated by blockade of a CCK receptor unrelated to stimulation of digestive enzyme secretion by the acinar cell but, perhaps, regulating intracellular metabolism in some way. Thus the action of proglumide and related CCK receptor antagonists might be to put the acinar cell "metabolically at rest."
Another potential clinical use for CCK receptor antagonists may be in the treatment of the pain resulting from chronic pancreatitis if the level of pain is related in some patients to the level of acinar cell metabolic activity or digestive enzyme secretion. Treatment with high doses of pancreatic enzyme supplements have been reported to reduce pain in some patients with chronic pancreatitis [18] . This effect has been hypothesized to be due to enhancement of serine protease-mediated feedback inhibition of CCK secretion by the proximal small intestine. If this explanation proves to be correct, administration of CCK receptor antagonists would be expected to provide a more consistent and, perhaps, greater, beneficial effect.
Unfortunately, despite these tantalizing prospects for the use of CCK receptor antagonists in acute or chronic pancreatitis, their ultimate clinical value (if any) remains to be established.
SOMATOSTATIN ANALOGS
A peptide agonist already in clinical use is the somatostatin analog octreotide, which has proven effective in the treatment of some pancreatic fistulas [19] and pseudocysts [20] , presumably primarily through diminishing water and electrocyte secretion by centroacinar and ductal epithelial cells in the pancreas. Octreotide is also being evaluated as a therapeutic agent to reduce pain in chronic pancreatitis in the hope that a decrease in the volume of pancreatic secretion will lead to diminished pain by decreasing the pressure in the pancreatic duct system. If this theory turns out to be validated, clinical development of recently described secretin receptor antagonists [21] could prove to be as effective as octreotide but more selective.
Somatostatin and its analogs have also been proposed for use in the treatment of acute pancreatitis [22] , with the rationale being either to reduce pancreatic enzyme secretion or to lessen the metabolic workload of acinar cells (a beneficial effect also hypothesized for CCK receptor antagonists). The clinical data are as yet too limited to determine whether this approach will be successful. If it is, however, it is more likely that the second rationale will account for its success rather than the first, because pancreatic enzyme secretion appears to be markedly reduced during the development of acute pancreatitis even in the absence of any pharmacologic intervention [23, 24] .
CONCLUSION
The increasing availability of potent and specific agonists and antagonists for regulatory gastrointestinal peptides now opens the way for studies evaluating the extent to which disordered regulatory processes are involved in the development of diseases of the pancreas. In addition, these agents provide the possibility that pancreatic inflammation (both acute and chronic) and its consequences could be treated more directly and effectively than is now possible.
